Oseltamivir Dosing in Children
For children ≥12 months, use weight-based dosing: 30 mg twice daily for ≤15 kg, 45 mg twice daily for 15-23 kg, 60 mg twice daily for 23-40 kg, and 75 mg twice daily for >40 kg for treatment (5 days); halve the frequency to once daily for prophylaxis (7-10 days). 1
Dosing by Age and Weight
Children ≥12 Months (Treatment: 5 days; Prophylaxis: 7-10 days)
The most recent 2024 AAP guidelines 1 provide clear weight-based dosing that supersedes older recommendations:
Treatment (twice daily):
- ≤15 kg: 30 mg
15-23 kg: 45 mg
23-40 kg: 60 mg
40 kg: 75 mg
Prophylaxis (once daily):
- Same doses as treatment, but given once daily instead of twice daily
The 2019 guidelines 2 note that the oral suspension concentration is 6 mg/mL (updated from the older 12 mg/mL formulation), so a 30 mg dose = 5 mL, 45 mg = 7.5 mL, 60 mg = 10 mL, and 75 mg = 12.5 mL.
Infants <12 Months
For infants 9-11 months: 3.5 mg/kg/dose twice daily for treatment; 3.5 mg/kg/dose once daily for prophylaxis 2, 1
For term infants 0-8 months: 3 mg/kg/dose twice daily for treatment; 3 mg/kg/dose once daily for prophylaxis (ages 3-8 months only) 2, 1
For infants <3 months: Prophylaxis is not recommended unless the situation is judged critical due to limited safety data 2, 1
Premature Infants
Dosing for preterm infants requires adjustment based on postmenstrual age (PMA) 2, 1:
- <38 weeks PMA: 1.0 mg/kg/dose twice daily
- 38-40 weeks PMA: 1.5 mg/kg/dose twice daily
40 weeks PMA: 3.0 mg/kg/dose twice daily
Critical caveat: Premature infants have slower oseltamivir clearance due to immature renal function, and standard term infant doses can lead to dangerously high drug concentrations 3. The evidence notes that observed drug concentrations were highly variable among premature infants, and these recommendations are based on very limited data 3.
Renal Impairment Adjustments
For creatinine clearance 10-30 mL/min 3, 1:
Treatment: 75 mg once daily for 5 days (instead of twice daily)
Prophylaxis: 30 mg once daily OR 75 mg once every other day for 10 days after exposure
The FDA label 4 confirms these renal dosing adjustments apply to patients ≥13 years and adults. Pediatric-specific renal dosing is not available in the package insert 1, though CDC dosing tables may be useful for children >40 kg who qualify for adult doses.
Formulation and Administration
Oseltamivir is available as:
- Capsules: 30 mg, 45 mg, 75 mg 2, 1, 4
- Oral suspension: 6 mg/mL concentration (360 mg powder reconstituted) 2, 1, 4
Administration tips:
- Can be given without regard to meals, though administration with food may improve GI tolerability 3, 2, 1
- If commercial suspension unavailable, capsules can be opened and mixed with sweetened liquid to mask bitter taste, or pharmacies can compound a suspension 3, 2
- For infants <1 year, use an appropriate measuring device (3-mL or 5-mL oral syringe) instead of the supplied syringe 1
Key Clinical Considerations
Duration of therapy:
- Treatment: 5 days for all ages 2, 1, 4
- Prophylaxis: 7 days is now standard (updated from older 10-day recommendations) 1, though 10 days may still be used in institutional outbreaks 2
Age-based dosing alternative: If weight is unknown for infants <1 year, age-based dosing can be used 3:
- 0-3 months: 12 mg (treatment only)
- 3-5 months: 20 mg
- 6-11 months: 25 mg
FDA approval status: Oseltamivir is FDA-approved for children ≥2 weeks of age 2, 5. The Emergency Use Authorization for infants <1 year expired in 2010, but the drug remains appropriate for use when indicated 3.
Resistance monitoring: While most influenza strains remain susceptible to oseltamivir, resistance can emerge (particularly H275Y mutation in H1N1pdm09) 2, 6. Local surveillance data should guide empiric treatment decisions.
Common adverse events in children include nausea, vomiting, headache, skin reactions, and diarrhea (particularly in children <1 year) 1. Neuropsychiatric events have been reported, and patients should be monitored for signs of confusion or abnormal behavior 4.